Discounted Cash Flow
Biogen Inc.
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $13.3b | $4.3b | $4.5b | 32.3% | $16.96 |
| 2017 | $14.3b (7.2%) | $2.9b (-31.4%) | $4.3b (-5.7%) | 20.7% (-36.0%) | $11.94 (-29.6%) |
| 2018 | $15.6b (9.6%) | $5.1b (74.5%) | $6.3b (47.1%) | 32.9% (59.2%) | $21.63 (81.2%) |
| 2019 | $16.7b (6.9%) | $6.8b (32.9%) | $7.6b (21.2%) | 41.0% (24.4%) | $31.47 (45.5%) |
| 2020 | $15.6b (-6.5%) | $4.6b (-32.1%) | $4.4b (-42.0%) | 29.8% (-27.3%) | $24.86 (-21.0%) |
| 2021 | $12.8b (-18.3%) | $1.8b (-61.1%) | $3.9b (-11.1%) | 14.2% (-52.4%) | $10.44 (-58.0%) |
| 2022 | $11.8b (-7.4%) | $3.5b (95.8%) | $1.3b (-66.2%) | 29.9% (111.4%) | $20.96 (100.8%) |
| 2023 | $11.4b (-3.3%) | $1.3b (-61.9%) | $1.5b (11.0%) | 11.8% (-60.6%) | $8.02 (-61.7%) |
| 2024 | $11.2b (-1.6%) | $1.9b (40.6%) | $3.2b (114.3%) | 16.9% (42.9%) | $11.21 (39.8%) |
| 2025 | $11.5b (2.2%) | $1.5b (-20.8%) | $2.4b (-24.7%) | 13.1% (-22.5%) | $8.83 (-21.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in EUR. Values above are converted to USD for comparison with the US-listed share price.
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.